TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12930173

Group type: EXPERIMENTAL
Intervention: Static stretching (STR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonstretching (NSTR)
Number of subjects: 18
Study: 10373865

Group type: EXPERIMENTAL
Intervention: Catheter removal at 2400 hours (group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Catheter removal at 0600 hours (group B)
Number of subjects: 48
Study: 8679358

Group type: EXPERIMENTAL
Intervention: ketamine 0.15 mg kg‐1
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ketamine 0.30 mg kg‐1
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 1651993

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Cisplatin-based therapy
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Good PS with hemoglobin level >= 11 g/dL and age > 47 years
Number of subjects: 2531

Group type: COMPARATOR
Intervention: Good PS
Number of subjects: 2531

Group type: EXPERIMENTAL
Intervention: Hemoglobin level >= 11.0 g/dL, normal LDH, normal calcium, single metastatic site
Number of subjects: 2531
Study: 7038553

Group type: EXPERIMENTAL
Intervention: 200 mg UDPG
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 30943958

Group type: EXPERIMENTAL
Intervention: Women's Circles intervention (10 sessions co-designed and facilitated by circle leaders)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Women's Circles intervention
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Women's Circles intervention (more sessions attended)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 155
Study: 29029679

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 248

Group type: COMPARATOR
Intervention: Psychoeducation and supportive therapy (PST)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Behavior therapy and PST
Number of subjects: 248
Study: 25644279

Group type: EXPERIMENTAL
Intervention: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg for 12 or 24 weeks (subtype 1b)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg for 12 weeks (genotype 2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ombitasvir 25 mg plus paritaprevir/ritonavir 100/100 mg or 150/100 mg (genotype 2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Number of subjects: 110
Study: 24477392

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 15 sessions at a dosage of 18 J per session over the carpal tunnel area with neutral wrist splint
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo laser therapy with neutral wrist splint
Number of subjects: 66
Study: 22468576

Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy for psychosis (CBTp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group social skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 18930200

Group type: EXPERIMENTAL
Intervention: Stimulation group (injection of culture medium)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: SEET group (injection of embryo culture supernatant)
Number of subjects: 144

Group type: COMPARATOR
Intervention: BT group (control)
Number of subjects: 144
Study: 17098835

Group type: EXPERIMENTAL
Intervention: tolcapone 100 mg three times daily
Number of subjects: 677

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 677
Study: 10916805

Group type: EXPERIMENTAL
Intervention: Ambulatory cataract surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Inpatient cataract surgery
Number of subjects: 44
Study: 8737616

Group type: EXPERIMENTAL
Intervention: Gn-RH-a for 3 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 36
Study: 1443864

Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone (200 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (control inhalation)
Number of subjects: 0
Study: 3840660

Group type: EXPERIMENTAL
Intervention: Halothane (n=46)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Enflurane (n=43)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isoflurane (n=35)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 66
Study: 31719087

Group type: EXPERIMENTAL
Intervention: Behavioural intervention from a certified peer recovery support specialist
Number of subjects: 650

Group type: COMPARATOR
Intervention: Behavioural intervention from a licensed clinical social worker (LCSW)
Number of subjects: 650
Study: 30185197

Group type: EXPERIMENTAL
Intervention: Educational outreach visits (15 to 20 minutes per guideline)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Passive guideline dissemination (access to guidelines via website)
Number of subjects: 239
Study: 26589241

Group type: EXPERIMENTAL
Intervention: Participants with persistent albuminuria (15.8%)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Participants without albuminuria
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Participants with intermittent albuminuria
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Baseline albuminuria
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Persistent albuminuria
Number of subjects: 502
Study: 23978408

Group type: EXPERIMENTAL
Intervention: Home visits with calls
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Telephone calls only
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control (placebo calls)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Home visits and calls combined
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: All groups (home, call, control)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Study groups (home and call)
Number of subjects: 610
Study: 22647925

Group type: EXPERIMENTAL
Intervention: 2.0‐mm 3‐dimensional miniplate (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2.0‐mm conventional miniplate (group B)
Number of subjects: 50
Study: 19924399

Group type: EXPERIMENTAL
Intervention: Navigation-assisted gap balancing
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional measured resection
Number of subjects: 116
Study: 18450803

Group type: EXPERIMENTAL
Intervention: Continuous infusion of vancomycin (25 mg/kg/day or 15 mg/kg/day in period 1; 30 mg/kg/day or 20 mg/kg/day in period 2)
Number of subjects: 145
Study: 15930039

Group type: EXPERIMENTAL
Intervention: Successful thrombolysis
Number of subjects: 362

Group type: COMPARATOR
Intervention: Rescue PTCA
Number of subjects: 362
Study: 12501480

Group type: EXPERIMENTAL
Intervention: Inhibitors of cholinesterase plus selective serotonin reuptake inhibitors (SSRIs) (citalopram HBr, 20 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhibitors of cholinesterase (Donepezil, 5 mg/day)
Number of subjects: 50
Study: 10607980

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 121
Study: 7495344

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic hypertension alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Systemic hypertension alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both pulmonary and systemic hypertension
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Normal pulmonary artery and systemic pressures
Number of subjects: 48
Study: 2029996

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline, 0.3 ml/kg)
Number of subjects: 20
Study: 31999480

Group type: EXPERIMENTAL
Intervention: Peppermint odor stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Auditory takeover modality
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tactile takeover modality
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 60
Study: 31013009

Group type: EXPERIMENTAL
Intervention: H9N2-specific antibody detection
Number of subjects: 80
Study: 28488353

Group type: EXPERIMENTAL
Intervention: Individualized management programme comprising nurse-led education and review of care plans by stroke specialists in addition to usual care
Number of subjects: 563

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 563
Study: 26154851

Group type: EXPERIMENTAL
Intervention: 30 mcg of EE + DRSP
Number of subjects: 44

Group type: COMPARATOR
Intervention: 20 mcg of EE + DRSP
Number of subjects: 44
Study: 23642945

Group type: EXPERIMENTAL
Intervention: Bee venom acupuncture point injection (0.005% diluted in normal saline, 0.05 ml at each point, twice-weekly for three weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control group, twice-weekly for three weeks)
Number of subjects: 16
Study: 22121857

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 2 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 80
Study: 21029347

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matched placebo for 4 weeks
Number of subjects: 60
Study: 17379122

Group type: EXPERIMENTAL
Intervention: Trachlight (TL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GlideScope (GS)
Number of subjects: 60
Study: 15613678

Group type: EXPERIMENTAL
Intervention: Presence of A2 allele
Number of subjects: 1257
Study: 11875051

Group type: EXPERIMENTAL
Intervention: MMP1 G‐1607GG allele
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Haplotypes of MMP1 G‐1607GG and MMP12 Asn357Ser
Number of subjects: 590
Study: 9790160

Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg daily increasing up to 225 mg daily)
Number of subjects: 17
Study: 8669887

Group type: EXPERIMENTAL
Intervention: FEMP + PSK
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: FEMP + LMS
Number of subjects: 227

Group type: COMPARATOR
Intervention: FEMP
Number of subjects: 227
Study: 2212186

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-directive psychotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 121
Study: 475947

Group type: EXPERIMENTAL
Intervention: Enteric-coated prednisolone tablets (shellac based)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteric-coated prednisolone tablets (cellulose acetate phthalate based)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain prednisolone
Number of subjects: 0
Study: 31416771

Group type: EXPERIMENTAL
Intervention: e‐health and telephone group (e‐HT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: telephone only group (TO)
Number of subjects: 65
Study: 30915462

Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment for 52 weeks
Number of subjects: 20
Study: 29086522

Group type: EXPERIMENTAL
Intervention: Telemedicine with Wi-Fi scales, text messaging (texting)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Telemedicine with Wi-Fi scales
Number of subjects: 196

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Text messaging (texting)
Number of subjects: 196
Study: 25467560

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks without ribavirin
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) plus Elbasvir (20 mg or 50 mg) for 12 weeks with ribavirin
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 8 weeks without ribavirin
Number of subjects: 218

Group type: COMPARATOR
Intervention: Grazoprevir (100 mg) plus Elbasvir (50 mg) for 12 weeks
Number of subjects: 218
Study: 23414745

Group type: EXPERIMENTAL
Intervention: Low-intensity muscle strength training of the quadriceps and hamstrings using an isokinetic dynamometer (20 to 30% of peak torque)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aerobic-type training with a cycle ergometer
Number of subjects: 32
Study: 22179158

Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (65-75% HR(max)) for 30 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control session (no exercise)
Number of subjects: 10
Study: 19545446

Group type: EXPERIMENTAL
Intervention: Practice nurse-led collaborative care
Number of subjects: 900

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 900
Study: 16800964

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 731
Study: 15553108

Group type: EXPERIMENTAL
Intervention: Test tablet (levothyroxine sodium tablets 200 microg; Eferox)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reference tablet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 25

Group type: COMPARATOR
Intervention: Test tablet vs Reference tablet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Test tablet vs Oral solution
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Triiodothyronine
Number of subjects: 25
Study: 12240665

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9007343

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine and 1:100,000 norepinephrine (Mepivanor)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 1% tetracaine, 1:4,000 adrenaline, and 4% cocaine (TAC)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 1% lidocaine infiltration
Number of subjects: 71

Group type: COMPARATOR
Intervention: TAC
Number of subjects: 71

Group type: COMPARATOR
Intervention: Mepivanor
Number of subjects: 71
Study: 8305640

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg every 12 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg every 12 h) + Aspirin (75 mg/day)
Number of subjects: 15
Study: 3329964

Group type: EXPERIMENTAL
Intervention: Cisapride 4 mg or 8 mg orally three times daily for two successive three-week periods
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo orally three times daily for two successive three-week periods
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 56
Study: 31486332

Group type: EXPERIMENTAL
Intervention: HOM-HEMP intervention
Number of subjects: 10
Study: 30725015

Group type: EXPERIMENTAL
Intervention: Self-administered rehabilitation program
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 271
Study: 27717635

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50μg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100μg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 150μg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30mg before leaving the operating room and 15mg every 6h for 24h
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (patient-controlled)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100μg and 150μg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50μg, 100μg, 150μg
Number of subjects: 144
Study: 24131665

Group type: EXPERIMENTAL
Intervention: 60% xenon anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.0% sevoflurane anaesthesia
Number of subjects: 0
Study: 22820341

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left PPC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS over left PPC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cathodal tDCS over left PPC
Number of subjects: 30

Group type: COMPARATOR
Intervention: tDCS over right PPC (anodal, sham, cathodal)
Number of subjects: 30
Study: 20429647

Group type: EXPERIMENTAL
Intervention: SRPL (SRP and laser)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: L (laser)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SRP (SRP only)
Number of subjects: 19

Group type: COMPARATOR
Intervention: C (no treatment)
Number of subjects: 19
Study: 18480686

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg PO twice a day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16260821

Group type: EXPERIMENTAL
Intervention: Reality orientation therapy combined with donepezil
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (donepezil only)
Number of subjects: 79
Study: 11868799

Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDI + SP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NEB
Number of subjects: 12
Study: 12905915

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse used twice daily for 21 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse used with routine daily brushing for 180 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 40
Study: 7495392

Group type: EXPERIMENTAL
Intervention: Ibopamine (IBO) 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study: 2114069

Group type: EXPERIMENTAL
Intervention: Intravesical adriamycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral ftorafur
Number of subjects: 40
Study: 677195

Group type: EXPERIMENTAL
Intervention: Continuous fetal heart rate monitoring
Number of subjects: 504

Group type: COMPARATOR
Intervention: Intermittent auscultation
Number of subjects: 504
Study: 30144228

Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both WET and CPT
Number of subjects: 126
Study: 27289009

Group type: EXPERIMENTAL
Intervention: Weight-neutral program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Weight-loss program
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both programs
Number of subjects: 80
Study: 24059906

Group type: COMPARATOR
Intervention: NaFeEDTA-fortified oat beverage without vitamin C
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified oat beverage with vitamin C
Number of subjects: 19
Study: 22764218

Group type: EXPERIMENTAL
Intervention: Personalised emails inviting interaction about chlamydia testing
Number of subjects: 704

Group type: COMPARATOR
Intervention: Regular impersonal emails
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Engaged in email interaction
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (condom use, changes in knowledge and attitudes)
Number of subjects: 704
Study: 20644719

Group type: EXPERIMENTAL
Intervention: Perceptual discrimination training
Number of subjects: 0
Study: 18567279

Group type: EXPERIMENTAL
Intervention: Pycnogenol (60 mg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 16468483

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 containing toothpaste and mouthrinse (combined group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: AmF/SnF2 containing toothpaste only (toothpaste only group)
Number of subjects: 42
Study: 12459934

Group type: EXPERIMENTAL
Intervention: Strontium ranelate 1 g/day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10650257

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Band ligation plus sclerotherapy
Number of subjects: 80
Study: 8892168

Group type: EXPERIMENTAL
Intervention: Asymptomatic giardiasis group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (anemia without intestinal parasitosis)
Number of subjects: 2
Study: 1495291

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (target hematocrit 32%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conservative transfusion strategy (target hematocrit <25%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conservative transfusion strategy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Conservative transfusion strategy with transfusion between exercise tests
Number of subjects: 39
Study: 6862578

Group type: EXPERIMENTAL
Intervention: DAMME (metenkephalin analog)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DAMME
Number of subjects: 16
Study: 31397022

Group type: EXPERIMENTAL
Intervention: Epilepsy nurse competency framework intervention
Number of subjects: 312

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 312
Study: 27593709

Group type: EXPERIMENTAL
Intervention: Bilateral stimulation group (500 pulses of 10 Hz rTMS over ipsilesional and contralesional motor cortices)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unilateral stimulation group (500 pulses of 10 Hz rTMS over ipsilesional motor cortex and sham rTMS over contralesional hemisphere)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham stimulation group (sham rTMS at bilateral motor cortices)
Number of subjects: 35
Study: 27282084

Group type: EXPERIMENTAL
Intervention: Immobilized group (8h left hand immobilization)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (normal limb use)
Number of subjects: 21
Study: 24515912

Group type: EXPERIMENTAL
Intervention: Rehabilitation exercise therapy combined with total glucosides form Shaoyao Gancao decoction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rehabilitation exercise therapy only (control group)
Number of subjects: 0
Study: 22926597

Group type: EXPERIMENTAL
Intervention: D-MPH-ER 30 mg/day
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: D-MPH-ER 20 mg/day
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165